Table 1.
Pathway Analysis of Genes Dysregulated in RAMP1 Knockdown PC3 Cells
| Variable | No. of genes | Expected | Enriched | Adjusted P value |
|---|---|---|---|---|
| KEGG | ||||
| Pathways in cancer | 23 | 5.62 | 4.09 | 1.37 × 10−6 |
| MAPK signaling pathway | 14 | 4.58 | 3.06 | 0.0016 |
| Endocytosis | 16 | 3.18 | 5.02 | 6.52 × 10−6 |
| Spliceosome | 11 | 2.18 | 5.05 | 0.0004 |
| Neurotrophin signaling pathway | 10 | 2.15 | 4.66 | 0.001 |
| Prostate cancer | 8 | 1.52 | 5.28 | 0.001 |
| Small-cell lung cancer | 8 | 1.43 | 5.59 | 0.001 |
| Chronic myeloid leukemia | 8 | 1.28 | 6.26 | 0.0009 |
| Pancreatic cancer | 7 | 1.23 | 5.71 | 0.0016 |
| Glioma | 7 | 1.11 | 6.32 | 0.001 |
| WIKI Pathways | ||||
| EGFR1 signaling pathway | 20 | 3.03 | 6.6 | 1.95 × 10−9 |
| Insulin signaling | 10 | 2.72 | 3.67 | 0.0024 |
| B-cell receptor signaling pathway | 12 | 2.69 | 4.46 | 0.0002 |
| Regulation of actin cytoskeleton | 10 | 2.43 | 4.11 | 0.0013 |
| mRNA processing | 11 | 2.32 | 4.75 | 0.0002 |
| Adipogenesis | 9 | 2.26 | 3.97 | 0.0027 |
| Androgen receptor signaling pathway | 11 | 1.96 | 5.62 | 8.22 × 10−5 |
| IL-6 signaling pathway | 10 | 1.67 | 5.99 | 9.31 × 10−5 |
| Senescence and autophagy | 10 | 1.02 | 9.79 | 1.79 × 10−6 |
| Id signaling pathway | 6 | 0.87 | 6.91 | 0.0013 |
| Pathway Commons | ||||
| Glypican pathway | 23 | 7.42 | 3.1 | 0.0001 |
| Glypican 1 network | 23 | 6.88 | 3.34 | 4.95 × 10−5 |
| IFN-γ pathway | 19 | 5.82 | 3.26 | 0.0004 |
| TRAIL signaling pathway | 17 | 5.06 | 3.36 | 0.0006 |
| Signaling by GPCR | 13 | 3.32 | 3.92 | 0.0008 |
| EGFR1 | 14 | 2.45 | 5.71 | 2.33 × 10−5 |
| Sphingosine 1-phosphate pathway | 10 | 1.92 | 5.2 | 0.0007 |
| Signaling by EGFR | 10 | 1.12 | 8.9 | 2.33 × 10−5 |
| Synaptic transmission | 7 | 0.92 | 7.61 | 0.0008 |
| IL-6–mediated signaling events | 7 | 0.77 | 9.14 | 0.0004 |
GPCR, G protein-coupled receptor; Id, inhibitor of DNA binding; IFN, interferon; KEGG, Kyoto Encyclopedia of Genes and Genomes; TRAIL, TNF-related apoptosis-inducing ligand.